Vatalanib similarly targets multiple VEGFRs and PDGFRs, with relatively greater selectivity against VEGFR-2 and ex vivo activity against CD34+ AML blasts, via inhibition of the PI3K/Akt pathway (Weidenaar et al., 2013). This evidence concerns the gene CD34 and acute myeloid leukemia.